Table of Contents 
Section 1. 
Introduction: Clinical and Biological Aspects of Cystic Fibrosis and Rationale 
for Gene Therapy For the Pulmonary Manifestations of Cystic Fibrosis 
Section 2. 
Construction, Characterization and Production of the Recombinant Adenoviral 
Vector, AvlCF2, Expressing the Human Cystic Fibrosis Transmembrane 
Conductance Regulator cDNA 
Section 3. 
Preclinical Evaluation of the AvlCF2 Vector Supporting its Use in the Treat- 
ment of the Respiratory Manifestations of Cystic Fibrosis 
Section 4. 
Evaluation of the Safety of the AvlCF2 Vector Mediated Gene Therapy For 
Cystic Fibrosis 
Section 5. 
Experimental Design of the Human Protocol 
Section 6. 
Figures 
Section 7. 
References 
Section 8. 
NIH Points to Consider 
Section 9. 
Appendices 
1 . Copies of Selected References 
2. Scientific Abstract of the Human Protocol 
3. Lay Statement Describing the Human Protocol 
4. Document Submitted to4he Local IRB and IBC 
5. Comments and Recommendations of Local Regulatory Committees 
6. Curricula Vitae For Key Professional Personnel 
7. Sequence of AV1CF2 
Recombinant DNA Research, Volume 17 
[357] 
